Cytotoxic Action of Acetyl-11-keto-β-Boswellic Acid (AKBA) on Meningioma Cells

 

 Buy Article Permissions and Reprints

Abstract

Acetyl-11-keto-β-boswellic acid (AKBA) is a naturally occurring pentacyclic triterpene isolated from the gum resin exudate of the tree Boswellia serrata (frankincense). Because pentacyclic triterpenes have antiproliferative and cytotoxic effects against different tumor types, we investigated whether AKBA would act in a similar fashion on primary human meningioma cell cultures. Primary cell cultures were established from surgically removed meningioma specimens. The number of viable cells in the absence/presence of AKBA was determined by the non-radioactive cell proliferation assay. The activation status of the proliferative cell marker, extracellular signal-regulated kinase-1 and -2 (Erk-1 and Erk-2) was determined by immunoblotting with the antibody that recognizes the activated form of these proteins. Treatment of meningioma cells by AKBA revealed a potent cytotoxic activity with half-maximal inhibitory concentrations in the range of 2 - 8 μM. At low micromolar concentrations, AKBA rapidly and potently inhibited the phosphorylation of Erk-1/2 and impaired the motility of meningioma cells stimulated with platelet-derived growth factor BB. The cytotoxic action of AKBA on meningioma cells may be mediated, at least in part, by the inhibition of the Erk signal transduction pathway. Because of the central role the Erk pathway plays in signal transduction and tumorigenesis, further investigation into the potential clinical use for AKBA and related boswellic acids is warranted.

References

• 1 Black P. Meningiomas.  Neurosurgery. 1993;  32 643-57
  CrossrefPubMedGoogle Scholar
• 2 Shu J, Lee J H, Harwalkar A J, Oh-Siskovic S, Stacey D W, Golubic M. Adenovirus-mediated transfer of dominant negative H-ras gene inhibits proliferation of primary meningioma cells.  Neurosurgery. 1999;  44 579-88
  PubMedGoogle Scholar
• 3 Hoshino R, Chatani Y, Yamori T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41/43-kDa mitogen activated protein kinase signaling pathway in human tumors.  Oncogene. 1999;  18 813-22
  CrossrefPubMedGoogle Scholar
• 4 Silverman E S, Drazen J M. The biology of 5-lipoxygenase: function, structure, and regulatory mechanisms.  Proc Assoc Am Physicians. 1999;  111 525-36
  CrossrefPubMedGoogle Scholar
• 5 Hong S H, Avis I, Vos M D, Martinez A, Treston A M, Mulshine J L. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.  Cancer Res. 1999;  59 2223-8
  PubMedGoogle Scholar
• 6 Boado R J, Pardridge W M, Vinters H V, Black K L. Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: Evidence for the expression of a multitranscript family.  Proc Natl Acad Sci USA. 1992;  89 904-48
  PubMedGoogle Scholar
• 7 Inamura T, Abe M, Ikezaki K, Fukui M. Leukotriene C4 contents, synthase and catabolic activity in human meningiomas.  Neurological Res. 1992;  14 405-10
  PubMedGoogle Scholar
• 8 Safayhi H, Mack T, Sabieraj J, Anazodo M I, Subramanian L R, Ammon H PT. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase.  J Pharmacol Exper Therap. 1992;  261 1143-6
  PubMedGoogle Scholar
• 9 Safayhi H, Sailer E -R. Anti-inflammatory actions of pentacyclic triterpenes.  Planta Medica. 1997;  63 487-93
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Sailer E R, Schweizer S, Boden S E, Ammon H PT, Safayhi H. Characterization of an acetyl-11-keto-β-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling.  Eur J Biochem. 1998;  256 364-8
  CrossrefPubMedGoogle Scholar
• 11 Glaser T, Winter S, Groscurth P, Safayhi H, Sailer E -R, Ammon H PT, Schabert M, Weller M. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity.  Br J Cancer. 1999;  80 756-65
  CrossrefPubMedGoogle Scholar
• 12 Hoernlein R F, Orlikowsky T, Zehrer C, Niethammer D, Seiler E -R, Simmet T, Dannecker G E, Ammon H PT. Acetyl-11-keto-β-boswellic acid induced apoptosis in HL60 and CCRF-CEM cells and inhibits topoisomerase I.  J Pharm Exp Ther. 1999;  288 613-9
  PubMedGoogle Scholar
• 13 Capodici C, Pillinger M H, Han G, Philips M R, Weismann G. Integrin-dependent homotypic adhesion of neutrophils. Arachidonic acid activates Raf-1/Mek/Erk via a 5-lipoxygenase-dependent pathway.  J Clin Invest. 1998;  102 165-75
  PubMedGoogle Scholar
• 14 Yu C -L, Tsai M H, Stacey D W. Serum stimulation of NIH3T3 cells induces the production of lipids able to inhibit GTPase-activating protein activity.  Mol Cell Biol. 1990;  10 6683-9
  PubMedGoogle Scholar
• 15 Toft N J, Arends M J. Apoptosis and necrosis in tumors. In: Apoptosis and Cancer, ed. by Martin SJ, Karger Landes Systems Basel, Switzerland; 1997: p. 25-44
  Google Scholar
• 16 Sebolt-Leopold J S, Dudley D T, Herrera R, Van Becelaere K, Wiland A, Gowan R C, Tecle H, Barrett S D, Bridges A, Przybranowski S, Leopold W R, Saltiel A R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo .  Nature Med. 1999;  5 810-6
  CrossrefPubMedGoogle Scholar
• 17 Lepley R A, Fitzpatrick F A. 5-Lipoxygenase contains a functional src homology 3-binding motif that interacts with the src homology 3 domain of Grb2 and cytoskeletal proteins.  J Biol Chem. 1994;  269 24 163-8
  PubMedGoogle Scholar
• 18 Provost P, Samuelsson B, Radmark O. Interaction of 5-lipoxygenase with cellular proteins.  Proc Natl Acad Sci USA. 1999;  96 1881-5
  CrossrefPubMedGoogle Scholar
• 19 Kang L -T, Vanderhoek J Y. Mono(S) hydroxy fatty acids: novel ligands for cytosolic actin.  J Lipid Res. 1998;  39 476-82
  PubMedGoogle Scholar
• 20 Streffer J R, Bitzer M, Schabet M, Dichgans J Weller M. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15.  Neurology. 2001;  56 1219-21
  CrossrefPubMedGoogle Scholar
• 21 Winking M, Sarikaya S, Rahmanian A, Jodicke A, Boker D K. Boswellic acids inhibit glioma growth: a new treatment option?.  J Neurooncol. 2000;  46 97-103
  CrossrefPubMedGoogle Scholar

Mladen Golubic,M.D., Ph. D. 

Cleveland Clinic Foundation

Department of Neurosurgery

9500 Euclid Avenue/ND4-52A

Cleveland

OH 44195

USA

Phone: +1 (216) 445-0550

Fax: +1 (216) 444-2682

Email: golubim@ccf.org